Agios Pharmaceuticals reports Q1 EPS ($1.69), consensus ($1.79)

Reports Q1 revenue $20.75M, consensus $13.65M. Reports Q1 Cash, cash equivalents, and marketable securities $1.045B. “Our Q1 performance reflects strong execution and significant progress against our 2026 strategic objectives,” said Brian Goff, CEO, Agios. “The solid early momentum of our U.S. commercial launch of AQVESME in thalassemia highlights both the medicine’s clinical value and strong community reception. Additionally, following collaborative engagement with the FDA, we now plan to submit our mitapivat sNDA for sickle cell disease under the U.S. accelerated approval pathway in the second quarter. 2026 marks an important growth inflection point for Agios as we continue to build a sustainable rare disease company that is rooted in hematology and focused on delivering differentiated medicines that create meaningful long-term value for patients and shareholders.”